Novel Gout Drug Aces Mid-Stage Tests
SAN DIEGO — An investigational once-daily oral agent that inhibits urate transporter-1 (URAT1) as a means of forcing uric acid excretion showed good efficacy and safety in a pair of phase II trials reported here. In one of these studies, the new product, called AR882 for the time being, reduced serum urate by 40% to […]
Once-Weekly Insulin Icodec Bests Daily Insulin Options for Type 2 Diabetes
SAN DIEGO — Investigational once-weekly insulin icodec outperformed once-daily insulin glargine U100 when it came to glycemic control in type 2 diabetes, the phase IIIa ONWARDS 1 trial found. Over the course of 52 weeks, people with type 2 diabetes saw a greater average reduction in HbA1c with icodec compared with glargine U100 (estimated between-group […]
Nonimmunosuppressive Therapy Bests ARB for Cutting Proteinuira in IgA Nephropathy
AUSTIN, Texas — Once-daily sparsentan (Filspari) was better at reducing proteinuria than standard treatment in IgA nephropathy, according to a prespecified interim analysis of the PROTECT trial. By week 36 of treatment in the phase III study, patients on sparsentan saw a 49.8% reduction from baseline in urine protein-creatinine (UP/C) ratio compared with only a […]